WVP
RIGL icon

Worth Venture Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Worth Venture Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,781
Closed -$622K – 129
2020
Q4 		$622K Buy
+17,781
New +$515K 0.49% 56
2020
Q3 		– Sell
-21,404
Closed -$391K – 134
2020
Q2 		$391K Sell
21,404
-11,935
-36% -$215K 0.19% 72
2020
Q1 		$520K Buy
33,339
+32,073
+2,533% +$683K 0.32% 45
2019
Q4 		$27K Sell
1,266
-23,803
-95% -$490K 0.01% 80
2019
Q3 		$469K Buy
25,069
+2,275
+10% +$47K 0.27% 45
2019
Q2 		$595K Buy
22,794
+880
+4% +$19.9K 0.33% 44
2019
Q1 		$463K Buy
21,914
+13,174
+151% +$301K 0.26% 50
2018
Q4 		$200K Buy
8,740
+7,740
+774% +$218K 0.15% 65
2018
Q3 		$32K Buy
+1,000
New +$30K 0.02% 147

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Worth Venture Partners's RIGL Position: Q1 2021 in Review

Worth Venture Partners sold out of Rigel Pharmaceuticals (RIGL) in Q1 2021, closing a stake of 17,781 shares — an estimated $622K sold.

Worth Venture Partners first reported a position in RIGL in Q3 2018 and held it in 9 quarters. The position peaked at $622K in Q4 2020. 152 funds tracked by Wall St. Rank hold RIGL as of Q1 2021.

  • Worth Venture Partners reported no remaining Rigel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Worth Venture Partners sold 17,781 Rigel Pharmaceuticals shares in Q1 2021, an estimated $622K.
  • Worth Venture Partners first reported a position in Rigel Pharmaceuticals in Q3 2018 and held it in 9 quarters.
  • Worth Venture Partners's Rigel Pharmaceuticals position peaked at $622K in Q4 2020.
  • 152 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2021.

Based on Worth Venture Partners's 13F filing for Q1 2021, filed 17 May 2021.